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1. Introduction 
The prevalence of diabetes mellitus is increasing to epidemic proportions worldwide. 
Diabetic foot ulceration can affect up to 25 percent of people with diabetes mellitus 
throughout their lives. The most significant complication of foot ulceration is lower limb 
amputation, which arises from pre-existing ulcers in the majority of cases.  Despite current 
clinical care protocols for ulcer treatment, there exists a high amputation rate. This presents 
a major burden for individual patients’ health and well-being in addition to significant 
financial cost for health care systems. There is an urgent need for new medicinal products to 
treat diabetic ulcers. Cell-based therapies offer a novel treatment strategy to augment 
diabetic wound healing, increase ulcer healing rate and prevent amputation.  The field of 
tissue engineering has developed commercially available skin substitutes for diabetic 
cutaneous wound repair. These products have incorporated somatic cells delivered in a 
bioengineered scaffold. However, having been available for the last decade, the majority 
have demonstrated only moderate clinical benefit in small clinical trials. In comparison, 
stem and progenitor cell therapy offer the potential for accelerated wound repair in addition 
to structural skin regeneration with functional recovery.  
Stem cells have the ability to self-renew and differentiate into other cell types and are classified 
into adult stem and progenitor cells, embryonic stem cells and induced pluripotent stem cells. 
The mechanisms of action of stem and progenitor cells are not fully elucidated but include 1) 
differentiation to specialised cells e.g. skin cells of the dermis and epidermis 2) acting by 
paracrine or autocrine effects through the secretion of trophic factors e.g. the production of 
soluble mediators for neo-angiogenesis and 3) immuno-modulatory functions. Much research 
endeavour is determining the benefit of stem cell treatment on diabetic cutaneous wound 
healing with encouraging results in animal models. Regenerative medicine and tissue 
engineering specialties are rapidly elucidating the mechanisms of action of stem cells and 
translating the results of in-vitro and in-vivo experiments to human clinical trials. The 
requirements for success will be patient safety, clinical efficacy and convenience of use. 
The focus of this chapter is to review the area of topical stem and progenitor cell therapy as 
a treatment for non-healing diabetic foot ulcers. It will focus on adult stem cells as these are 
nearer to use in human trials and do not pose the ethical constraints associated with the use 
of embryonic stem cells. Topical treatment with endothelial progenitor cell (EPC) and 
mesenchymal stem cell (MSC) therapy is presented in this review, and more specifically the 
delivery of these cells using biomaterial scaffolds. The currently available cell therapy 
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products for wound repair will be presented. The case for adopting stem and progenitor cell 
therapy in research and treatment of diabetic foot ulcers will be discussed. The benefits of 
biomaterials and functionalised scaffolds for mediating cell therapy to a wound will be 
described. For both endothelial progenitor cells and mesenchymal stem cells, the potential 
mechanisms of action will be discussed with reference to key pre-clinical and clinical 
studies. The chapter will also describe strategies to enhance the therapeutic potential of stem 
and progenitor cells for wound healing. These will include the employment of matri-cellular 
proteins i.e. proteins associated with the extracellular matrix that mediate diverse biological 
functions, gene therapy, conditioned media experiments and the delivery of several cell 
types. A section of the chapter will focus on translational of these advanced biological 
medicines to clinical trials. This includes issues regarding pre-clinical animal models, 
optimal cell source, safety and regulatory approval. Finally the chapter will highlight the 
potential of cell based therapies in other conditions causing cutaneous wounding, i.e burns, 
decubitus ulcers and other rare blistering conditions e.g. epidermolysis  bullosa.  
2. The biology of cutaneous wounds 
The repair of cutaneous wounds is a highly complex biological process.   After injury, 
multiple biological pathways immediately become activated and are synchronised to 
respond.(Gurtner et al., 2008) Adult wound healing occurs by tissue repair with consequent 
scarring. The goal of adult wound healing is to repair a skin defect, to ensure the restoration 
of a barrier and to regain tensile strength. There is involvement of several cell types, 
cytokines and extra-cellular matrix components. The physiological overlapping pathways 
that are required for optimal wound healing include haemostasis (which occurs 
immediately on wounding), inflammation with cell migration and proliferation (neutrophils 
initially and subsequently macrophages). The proliferation of fibroblasts results in extra-
cellular matrix deposition. Remodeling and wound contraction occur once closure of the 
wound takes place. Angiogenesis (growth of new blood vessels from pre-existing blood 
vessels) and re-epithelialisation are central processes in wound healing. This is a superficial 
description of wound healing and conveys the complexity of the process, but highlights the 
potential for disruption in a difficult to heal wound. (Breen et al., 2008 ;Harding er al., 2002) 
The physiological response to acute cutaneous wounds usually takes 3-14 days to complete. 
(Liu et al., 2008) Wound healing involves activation of keratinocytes, fibroblasts, endothelial 
cells, macrophages and platelets.(Brem et al., 2007) Figure I details the stages of normal 
cutaneous wound healing. 
2.1 Diabetic wound healing 
Delayed wound healing as occurs in diabetes mellitus results from dysregulation of the 
normal healings pathways. The diabetic wound is complex with contribution from infection, 
neuropathy and impaired vascular supply. There are many physiological defects in diabetic 
wounds. These include decreased or impaired growth factor production, angiogenic 
response, macrophage function, collagen accumulation, epidermal barrier function, quantity 
of granulation tissue, keratinocyte, fibroblast migration and proliferation and bone healing. 
There is an imbalance between the accumulation of extra-cellular matrix components and 
their re-modeling by matrix metallo-proteinases.(Brem et al. 2007) In addition fibroblasts 
from diabetic wounds become senescent and show a decreased proliferative response to 
growth factors.(Falanga et al., 2005) There is a chronic inflammatory environment associated 
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with diabetic wounds. This is associated with a persistent increase in pro-inflammatory 
cytokines by various immune and non-immune cells and it is hypothesized that this blunts 
the acute, focused cytokine response needed to progress through the normal phases of 
wound healing.(Pradhan et al., 2009) 
 
 
Fig. I. Stages of normal wound healing with predominant cell types involved at each stage 
of process. The wound healing spectrum is a continuum with overlapping phases.  
2.2 Angiogenesis and wound Healing 
The impaired vascular supply associated with diabetes leads to poor blood flow at the 
wound site impeding the optimal endogenous reparative response (Jeffcoate & Harding 
2003) Impaired angiogenesis is a feature of diabetic wounds. In addition neovascularisation, 
or the de novo formation of new blood vessels is critical for granulation tissue formation 
and tissue regeneration in wound healing. (Gurtner et al., 2008) The impaired angiogenic 
response that occurs in diabetes mellitus leads to hypoxia at the wound site. Temporary 
hypoxia is requisite for normal wound healing. In the non-diabetic situation, hypoxia leads 
to activation of the transcription factor complex HIF-1ǂ (Hypoxia inducible factor-1ǂ), 
which leads to transcription of multiple genes required for successful wound healing. With 
diabetes, hyperglycaemia affects the stability and activation of HIF-1ǂ. This suppresses 
platelet-derived growth factor, vascular endothelial growth factor and transforming growth 
factor-ǃ, which are required for angiogenesis, in vitro and in vivo wound healing.(Botusan 
et al., 2008) 
2.3 Wound repair versus regeneration 
Adult wound healing occurs by repair. Wound repair leads to scarring and results in 
decreased tensile strength of wounds. Skin regeneration is the regeneration of wounds with 
restoration of the normal function and anatomy of skin. In biology, foetal wound repair is a 
regenerative process, and some vertebrate species demonstrate successful tissue 
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regeneration where the initial phase of wound repair is followed by perfect structural and 
functional regeneration of the organ. An example of this is Xenopus limb regeneration. The 
challenge for scientists is to produce tissue engineered products that exhibit extra-cellular 
matrix re-modeling characteristics seen in embryonic wound repair to produce functional 
and durable skin. (Metcalfe & Ferguson 2007) 
3. The case for novel topically applied stem and progenitor cell therapies  
3.1 Burden of diabetic ulceration 
There exists a growing global epidemic of diabetes mellitus. It is predicted that the prevalence 
of diabetes mellitus will be 4.4% of the global population or 366 million people by the year 
2030.(Wild et al., 2004) In 2010, the prevalence of diabetes in China was reported as 9.7%.(Yang 
et al., 2010) This will likely continue to increase based on the prevalence of obesity in 
populations. Foot ulcers can affect 12 to 25 percent of persons with diabetes mellitus 
throughout their lives.(Brem et al., 2006) Lower limb disease is the most common source of 
complications and hospitalisation in the diabetic population. (Boyko et al., 2006) Major lower 
limb amputations in patients with diabetes arise from preceding ulcers in 85% of cases. 
(Frykberg et al., 2006) The cost of treating diabetic foot ulcers creates a burden on healthcare 
resources. Boulton et al. reviewed the epidemiology and  cost of treating foot ulceration 
globally and one report estimated the cost of diabetic foot ulceration treatment including 
amputation at €10.9 billion  in the United States of America for the year 2001.(Boulton et al., 
2005) In addition to the cost to healthcare system budgets, for individual patients, the 
parameters of pain, social isolation, physical morbidity, restrictions in work capacity, and 
psychological well-being are negatively affected by leg ulceration.(Herber et al., 2007) 
3.2 Classification of diabetic ulcers 
Diabetic foot ulcers can be classified as ischaemic, neuropathic or neuro-ischaemic. The 
ability to heal ulcers is predicated on the restoration of an adequate blood supply. The 
typical angiographic pattern of ischaemic diabetic vasculopathy is occluded distal blood 
vessels. The optimal treatment of ischemic lower extremity ulcers is the restoration of blood 
flow.  This review paper focuses on treatment of neuropathic ulcers. Neuropathic ulcers 
develop due to distal sensory loss and consequent foot deformity. Ulceration develops at 
sites of excessive pressure predominantly under the first metatarsalphalangeal joint, in the 
majority due to unperceived trauma. Neuroischaemic ulcers are a combination of ischaemic 
and neuropathic ulcers.  
3.3 Current treatment strategies 
The management of the diabetic foot is complex requiring a multidisciplinary approach. A 
non-healing ulcer is an ulcer which has been present for > 8 weeks. Our group has reviewed 
the current standards of care required to investigate, treat and prevent diabetic foot 
ulceration and consequent amputation.(O'Loughlin et al.,2010) This manuscript highlights 
the benefit of routine examination and evaluation of the diabetic foot with identification of 
risk factors for ulceration. There are published risk stratification guidelines for diabetic foot 
ulceration based on the presence or absence of sensory loss, foot deformity and vascular 
insufficiency.(Boulton et al.,2008) The current standard care involves removal of pressure 
from the ulcer, restoration of blood flow if peripheral vascular disease is present, 
debridement of the ulcer and institution of antibiotic therapy to control infection. Topical 
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dressings, patient education, podiatry review, and orthotics are beneficial. A systematic 
review of the control arms of trials investigating novel treatments reported that for standard 
treatment of neuropathic diabetic ulcers, where blood supply had been adequate (as defined 
by a transcutaneous oxygen pressure of > 30 mmHg or an ankle-brachial index > 0.7), after 
20 weeks 31% of diabetic neuropathic ulcers were healed and at 12 weeks, 24% of 
neuropathic ulcers were completely healed.(Margolis et al., 1999)A protocol for the 
management of diabetic foot ulcers suggested treatment with growth factors and/or cellular 
therapy if wound healing is not is not observed after 2 weeks of standard therapy and a new 
epithelial layer has not formed.(Brem et al., 2004) 
3.4 Benefit of a cell-based therapy for non-healing diabetic ulcers 
It is evident that there is a critical clinical need to develop novel therapies for treatment of 
non-healing diabetic ulcers in order to prevent amputation and reduce the significant 
financial drain on healthcare budgets and burden on individuals health. The understanding 
of the patho-physiology of diabetic wound healing is important in the development of 
advanced wound healing treatments. It allows therapeutic targeting of the different phases 
of wound healing. Cell therapy may reverse the biological defects in diabetic wounds by 
acting as reservoirs for cell and growth factor production.  Gurtner et al. states that the 
ultimate solution to both under-healing and over-healing is likely to be administration of 
cells that retain the ability to elaborate the full complexity of biological signaling, together 
with the environmental cues that are needed to regulate the differentiation and proliferation 
of these cells (Gurtner et al., 2008) 
3.5 Limitations with current cell-based therapy 
To date clinical trials of topical cell based therapy for non-healing diabetic foot ulcers have 
yielded limited results. There are several reasons for this. One reason is methodological 
flaws in the clinical trials which have raised concerns over the validity of the results.  
Systematic reviews on skin replacement therapy have reported statistical benefit in wound 
healing endpoints. However there was a lack of information reported on safety, method of 
recruitment, randomization methods and blinding strategy for outcome assessments. There 
is a lack of power size calculations in some of the trials and little mention of dropouts in 
trial. The interventions did appear as safe as standard treatments. (Barber et al., 2008) It is 
felt that the deficiencies in clinical trials investigating skin replacement therapies for diabetic 
foot ulcers affect the conclusions of systematic reviews.(Blozik et al., 2008; Barber et al., 
2008;Teng et al., 2010) Further larger scale trials are required. 
However the lack of clinical success with these advanced medicinal products is most likely 
not solely due to the aforementioned flaws in trial design. The current somatic cell therapies 
do not address the underlying pathology in the diabetic wound i.e. chronic inflammation 
and impaired angiogenesis. An efficient blood supply is central to normal wound healing, 
and delayed or inefficient angiogenesis will prolong ulceration and increase the probability 
of amputation. The current cell treatments do not target angiogenesis (blood vessel 
formation from pre-existing blood vessels) or neo-vasculogenesis (de novo blood vessel 
formation). Somatic cells do not differentiate into other cell types of the dermis and 
epidermis.  The most frequently studied somatic cells include fibroblasts and keratinocytes. 
The employment of these cell treatments result in wound healing by repair and not by 
regeneration.  
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3.6 Potential superiority of treatment with stem and progenitor cells 
Endothelial progenitor cells are a newly described cell type involved in angiogenesis. They 
can migrate to a site of injury/ischaemia and play a central role in vascular maintenance, 
angiogenesis and neo-vascularisation. (Marrotte et al., 2010). Adult mesenchymal stem cell 
treatment holds promise as this cell type addresses the key wound impairments seen in non-
healing diabetic ulcers. They are immuno-modulatory and may create a more favourable 
inflammatory environment of the diabetic wound. They also promote angiogenesis by 
paracrine effects. Adult mesenchymal stem cells in diabetic wounds may in addition to 
beneficial paracrine activity, differentiate into other cell types e.g. epidermal keratincocytes, 
endothelial cells and pericytes in vivo.(Wu et al., 2007) In fact there is a growing body of 
evidence that the use of stem cells in wound healing in addition to augmenting wound 
repair, also promote skin regeneration and scarless wound healing.(Fu et al., 2009) 
4. Endothelial Progenitor Cells (EPCs) 
4.1 Background 
The discovery of putative EPCs by Ashara et al in 1997 (Asahara, et al., 1997) has 
illuminated the fields of vascular biology and diabetes related vascular dysfunction. For the 
first time, vasculogenesis or de novo blood vessel formation was determined to occur post-
natally, as previously it was assumed to occur only during embryogenesis. The delivery of 
EPCs to ischaemic sites in the body offers the possibility of successful treatment of diabetic 
vascular disease. Worldwide, research groups are testing the hypothesis that EPC therapy 
may treat peripheral vascular disease and prevent the progression of non-healing diabetic 
foot ulcers to amputation. These cells are suitable for autologous therapy without 
immunological rejection but this approach may be hindered due to disease associated cell 
dysfunction. 
EPC research is complicated by several issues. These include a lack of a standardised 
definition of the cell-type. The reports in the literature describe different identities, sources 
of isolation, culture methodologies and function. The cells maybe isolated from the 
peripheral blood, umbilical cord blood or bone marrow. They are referred to as progenitor 
cells or stem cells. In a comprehensive review, Hirschi et al. describe three different EPC 
types isolated from mononuclear cells.(Hirschi et al., 2008) This classification reflects the 
different cell types reported as EPCs. 
All three cell types are cultured in endothelial based media. The first cell type is named 
colony forming unit-Hill cells which arise from peripheral blood mononuclear cells which 
are non-adherent and give rise to a colony after 5 days in culture. The second cell type is a 
heterogenous collection of cells termed circulating angiogenic cells or early EPCs. These 
arise from mononuclear cells which are adherent to fibronectin or other matrix adhesion 
proteins  after 4-7 days. They do not form colonies and have a low proliferative  potential. 
They retain monocytic properties, secrete angiogenic factors and die after approximately 4 
weeks in culture.(Liew et al.,2008) The third cell type is the endothelial colony forming cell 
or late EPC. These cells are derived from  mononuclear cells that adhere to fibronectin and 
appear after 6-21 days. They display cobblestone morphology  and from blood vessels in 
vitro. They are highly proliferative. (Hirschi et al.,2008) The cells maybe further 
characterised by their ability to ingest acetylated low density lipoprotein and bind Ulex 
europaeusagglutinin 1 plant lectin. The different cell types may also be characterized by flow 
cytometry for surface immunophenotype. Late EPCs display markers CD 34, CD 133, 
VEGFR2, CD 31 and are negative for CD 45.  
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4.2 Benefit in wound healing 
Topical and systemic EPC therapy is beneficial in wound healing. The predominant 
mechanism is the augmentation of angiogenesis and neo-vascularisation.  Suh et al. 
reported that EPC therapy increased recruitment of monocytes and macrophages in 
addition to augmenting angiogenesis. (Suh et al., 2005) This highlights the benefit in early 
stages of wound healing. It is known that EPCs in wounds result in increased granulation 
tissue and wound closure. (Asai et al., 2006)It is intuitive that this is the case as a 
multitude of in vitro studies have shown the production of growth factors and cytokines 
from EPCs which are closely involved in wound healing. Table 1 presents the in vivo 
studies of EPC treatment for diabetic ulcers. These studies support the benefit of topical 
EPC therapy in diabetic wound healing. The mechanism is reported as via paracrine 
effect, direct incorporation in blood vessels and differentiation into endothelial cells. The 
field of topical EPC therapy is in the early stages with benefit demonstrated in these 
studies. Intramuscular EPC therapy has shown benefit in critical limb ischaemia. (Huang 
et al., 2005) Further research is required to determine the benefit of EPCs delivered in a 
biomaterial. In addition the standardisation of cell dose, definition of cell type and animal 
model is required. The use of human cells in immunocompromised animals are required 
to further elucidate therapeutic efficacy  
4.3 Mechanisms of actions 
4.3.1 Paracrine effect 
Early EPCs and Late EPCs may contribute to post-natal neovascularisation by secretion of 
angiogenic cytokines and growth factors. The secretome of EPCs contains cytokines and 
growth factors which stimulate wound healing by increasing proliferation, migration and 
cell survival of the different cell types required for wound healing i.e. keratinocytes, 
endothelial cells and fibroblasts. The conditioned media from EPC cultures revealed 
production of interleukin-8, Stromal-derived factor-1ǂ, vascular endothelial growth factor, 
platelet-derived growth factor and monocyte chemo-attractant protein-1(Di Santo et 
al.,2009;Barcelos et al., 2009;Zhang et al.,2009) These cytokines are central to cutaneous 
wound healing. Extensive secretome analysis can be undertaken using mass spectrometry to 
determine novel factors involved in EPC biology.(Pula et al., 2009) 
4.3.2 Direct incorporation in blood vessels 
The second mechanism of action is the direct incorporation of EPCs into the growing 
blood vessel wall or the differentiation of these cells into mature endothelial cells. This 
mechanism is associated with late EPCs This mechanism has been shown in animal 
models and may not be as significant as the paracrine effect of cell therapy. (Di Santo et 
al., 2009) The comparison of EPC conditioned media as compared to EPC therapy alone 
for wound healing is important. The transplantation of conditioned media or identified 
therapeutic factors would allow for protein-based therapy. One study compared 
conditioned media from EPCs to EPC treatment alone in an animal model of cutaneous 
wound healing. Injection of EPC conditioned media alone into the same diabetic wound 
in mice promoted wound healing and increased neovascularization to a similar extent as 
achieved with EPC transplantation alone.(Kim et al., 2010) However Marrote et al. did not 
find similar therapeutic efficacy with less wound healing effect from EPC conditioned 
media.(Marrotte et al., 2010)  
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4.4 Impaired angiogenesis in diabetes due to EPC dysfunction 
It is known that EPCs are decreased in number and dysfunctional in people suffering from 
diabetes mellitus. The decrease in number of circulating EPCs in people with diabetes is still 
under investigation but defects in the SDF-1ǂ/CXCR-4 pathway are becoming evident. 
(Tepper et al., 2010)There are defects in EPC recruitment to wound sites. This is due to 
decreased mobilisation from the bone marrow and decreased homing to cutaneous wounds. 
(Brem et al., 2007) With diabetes there is decreased EPC participation in neoangiogenesis 
and neovsacularisation. Studies show that there are defects in cell migration, adhesion and 
tube formation. (Tepper et al., 2002) There is also an increase in reactive oxygen species in  
EPCs isolated from diabetes patients leading to cellular dysfunction. There is a body of 
evidence indicating that diabetes mellitus related EPC cell dysfunction  represents a 
mechanism for impaired angiogenesis and impaired wound healing seen in diabetic 
patients.(Marrotte et al.,2010) The obstacle with autologus EPC therapy for diabetic 
complications is that there is a decreased number of cells available for transplantation. In 
addition, these autologous cells are dysfunctional. 
4.5 Strategies to increase EPC efficacy 
4.5.1 Topical delivery  
In normal healing EPCs are released into the circulation from the bone marrow in response 
to ischaemia and travel to sites of tissue injury and participate in angiogenesis. (Takahashi et 
al., 1999) Diabetes-related vascular dysfunction arises from impairments in EPC 
mobilisation and homing to sites of ischaemia and cutaneous wounds. This has been shown 
in animal models of diabetic wound healing. In mice with cutaneous wounds and 4 weeks 
of streptozocin induced hyperglycaemia, the levels of circulating EPCs were unchanged but 
the levels of bone marrow derived EPCs within the wound granulation tissue were 
decreased as compared to non-diabetic controls. The bone marrow derived EPCs from 
diabetic mice showed increased apoptosis and decreased proliferation in diabetic wound 
tissue as compared to non-diabetic controls. (Albiero et al., 2011) The topical delivery of cells 
to a wound would overcome this homing defect and in addition would allow for ex-vivo 
manipulation during the cell isolation process. This ex-vivo manipulation may restore the 
EPC functional defect and succeed in restoring diabetic wound healing to the non-diabetic 
phenotype. Systemic delivery of stem cell results in cells being taken from the circulation in 
the lungs, spleen and liver and not reaching the wound. (Sorrell & Caplan 2010) The high 
prevalence of peripheral vascular disease in people with disease also inhibits the 
intravascular delivery of cell to the affect foot ulcer.  The topical delivery of cells allows for 
concentrated doses of cells to be delivered to a skin wound and not become trapped in other 
sites in the body.  
4.5.2 Matricellular proteins: Osteopontin  
Osteopontin (OPN) is a matricellular protein and is involved in tissue repair and 
angiogenesis. These proteins modulate cell function by interacting with cell-surface 
receptors, proteases, hormones, and other bioeffector molecules, as well as with structural 
matrix proteins such as collagens (Bornstein, 2009) Decreased OPN is found in EPCs in 
diabetes mellitus. Dysfunction is reversed by exposure of EPCs to Osteopontin. (Vaughan 
EE, Liew A et al. 2011 In Press) Osteopontin is involved in angiogenesis. Osteopontin 
knockout mice have decreased myocardial angiogenesis in response to ischaemia and 
delayed recovery after hindlimb ischaemia. OPN is involved in wound healing. Wound 
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healing studies in osteopontin knockout mice show more residual debris and less matrix 
organisation than wildtype mice. (Scatena et al., 2007) OPN expression is associated with 
enhanced angiogenesis and collagenisation of the wound bed. Delay in diabetic wound 
healing may arise in part because of the low expression of OPN early in the wound bed 
after wounding, resulting in the reduced migration of immune cells to the site of injury 
leading to the accumulation of cell debris, decreased recruitment of endothelial cells, 
delayed angiogenesis and poor matrix organization. (Sharma et al., 2006)  
4.5.3 Biomaterials and encapsulated cells 
Adhesion to a substrate allows transplanted cell survival over even short time frames, and 
manipulation of major cellular processes (e.g., migration, proliferation, and 
differentiation) over longer time scales.(Mooney & Vanderburg 2008) Sufficient numbers 
of cells do not remain in place when applied to the wound surface.(Falanga, 2007). The 
use of biomaterials allows for more control in mediating delivery of cells to a wound. 
Current delivery options include injection of cells, delivery in extra-cellular matrix, 
delivery on a scaffold and delivery as part of a tissue engineering skin equivalents. 
(Sorrell & Caplan 2010) Silva et al. reported that delivery of EPCs using an alginate 
scaffold created a depot of endothelial progenitor cells which ensured sustained viability 
and function of cells in a mouse model of hind-limb ischaemia. This method was more 
successful than direct injection of cells alone. The vascular progenitor cells exit the 
biomaterial over time and repopulate damaged tissue and participate in the vascular 
network. (Silva et al., 2008) Cell encapsulation using biomaterials holds promise for both 
autologous and allogeneic cell therapy. The potential benefit of cell encapsulation with 
biomaterials includes sustained viability , the ability of the cell to avoid immune rejection, 
secrete therapeutic proteins and protect against mechanical stress(Orive et al., 
2003;Freimark et al., 2010) Encapsulation of adult mesenchymal stem cells permits cell 
survival, proliferation and differentiation.(Anderson et al., 2011) 
4.5.4 Co-culture, gene therapy and hyperoxia  
It is hypothesised that endothelial progenitor cells act as angiogenic support cells by their 
paracrine activity. Co-administration of EPCs with smooth muscle progenitor cells increased 
vessel density in a mouse model of hind-limb ischaemia to a greater degree than 
administration of either cell alone. (Foubert et al., 2008) Endothelial cells increase 
mesenchymal stem cell proliferation. (Saleh et al. 2010)  Gene therapy may rescue diabetic 
EPC dysfunction. Using an ex vivo gene transfer strategy, EPC cell cultures can serve as 
gene carriers and function as a temporal local production unit of de novo synthesized 
growth factors within the wound or skin replacement. (Dickens et al., 2010  )Increased 
reactive oxygen species and oxidative stress has been shown to give rise to the dysfunction 
of diabetic EPCs, leading to inhibition of cell proliferation, nitric oxide production, matrix 
metalloproteinase-9 activity and migration. Manganese superoxide dismutase gene therapy 
reverses this dysfunction restoring the cells ability to mediate angiogenesis and wound 
repair.(Marrotte et al., 2010) Hyperoxia increases nitric oxide mediated EPC activity. 
(Gallagher et al., 2007) The diabetes related dysfunction in hypoxia inducible factor -1ǂ 
which reduces vascular endothelial growth factor production (required for EPC activity) can 
be reversed by topical wound administration of the iron chelating agent desferoxamine. 
(Thangarajah et al., 2010) 
www.intechopen.com
 
Stem Cells in Clinic and Research 
 
588 
4.5.5 Increase number of EPCs 
Increasing EPC number for topical treatment increases the wound healing benefit of EPCs. 
(Marrotte et al., 2010) Granulocyte macrophage-colony stimulating factor (GM-CSF) 
increases monocyte derived peripheral blood EPCs. In-vitro animal studies reveal that 
proliferation of EPCs derived from the bone marrow can be accelerated by GM-CSF. (Wang 
et al., 2009) GM-CSF is routinely used in the patients receiving chemotherapy. It has been 
used in human clinical trials for investigation of autologous therapy in critical limb 
ischaemia. (Huang et al., 2005) In diabetic patients medications such as statins  and 
angiotensin-converting enzyme inhibitor therapy can increase EPC number. (Liew et al., 
2008) 
 
Wound Model EPC type Delivery Results Mechanism Ref. 
Diabetic 
immuno-
deficient mouse 
Ischemic ulcer 
Human fetal 
CD133+ 
progenitor 
cells 
Topical type 1 
collagen 
seeded with 
EPCs 
↑ wound closure
↑ angiogenesis 
Paracrine 
signalling 
{Barcelos, 
et al. 
2009} 
Diabetic Mouse 
Full thickness 
ulcer 
CD34+ EPCs Intradermal 
injection 
 
↑ wound closure.
↑epithelial 
coverage  ↑ 
vascularisation 
Not 
addressed 
{Sivan-
Loukiano
va et al., 
2003 } 
Diabetic Mouse 
full thickness 
ulcer 
bone marrow 
derived 
CD34+ EPCs
Intradermal 
injection 
 
↑vascularisation 
↑wound closure
Paracrine 
signalling 
(Stepanov
ic et al., 
2003) 
Diabetic 
immuno-
deficient mouse 
Full thickness 
ulcer 
Human 
umbilical 
cord blood 
EPCs 
Intradermal 
injection of 
EPCs 
and 
Topical EPC- 
CM 
↑angiogenesis 
↑ wound closure.
Conditioned 
media showed 
therapeutically 
equivalent effect
Paracrine 
signalling 
{Kim et 
al., 2010} 
Genetically 
Diabetic mouse 
full thickness 
ulcer 
Early EPCs Topical 
delivery of 
genetically 
modified 
EPCs 
↑wound closure 
↑angiogenesis 
↑ benefit with 
gene therapy and 
↑ cell dose 
Paracrine 
signaling 
EPCs present 
in capillaries 
(Marrotte, 
et al.) 
Diabetic mice 
full thickness 
cutaneous 
wounds 
Lineage 
Negative 
progenitor 
cells (EPCs) 
topically 
applied in a 
collagen 
scaffold 
↑Wound Closure
↑ Vascular 
density 
Differentiate 
into 
endothelial 
cells 
(Lin et al., 
2008) 
Human diabetic 
critical limb 
ischaemia and 
foot ulceration 
Autologous 
GM-CSF 
mobilized 
EPCs 
Intra-
muscular 
injections 
Ulcer healing, 
 
↑vessel 
density 
(Huang et 
al., 2005) 
Table I. Animal and human trials of EPC therapy for diabetic wounds 
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5. Mesenchymal Stem Cells (MSCs) 
MSCs are adult fibroblast-like cells that differentiate along multiple mesenchymal pathways 
when exposed to appropriate stimuli. They adhere to tissue culture plastic and express cell 
surface markers for CD 105, CD 73, CD 90, and fail to express cell surface markers for CD 45, 
CD 34, CD 14, CD 11b, CD 79a and CD 19.(Sorrell & Caplan 2010) MSCs were originally 
isolated from bone marrow by Friedenstein et al. in 1968.(Friedenstein et al., 1968) They may 
also be known as fibroblast colony forming units, marrow stromal cells,  multipotent adult 
progenitor cells, connective tissue progenitor cells or multipotent mesenchymal stromal 
cells. MSCs may be found in almost all postnatal organs and tissues, including adipose, 
periosteum, synovial membrane, synovial fluid, muscle, dermis, deciduous teeth, pericytes, 
trabecular bone, infrapatellar fat pad, articular cartilage and umbilical cord blood. (Si,  et al., 
2011) Stem cells located outside of the bone marrow are generally referred to as “tissue stem 
cells”. Tissue stem cells are located in sites called niches, which differ among various tissues 
e.g. a stem cell niche in the bulge area of hair follicles. (Cha & Falanga 2007) 
5.1 MSC treatment and wound healing  
The complex pathology of diabetic foot ulceration requires that novel treatments are 
developed. The factors which are central to ongoing ulceration include poor blood supply, 
inflammation and decreased functioning of resident wound healing cells. MSC treatment 
has been shown to augment angiogenesis, suppress inflammation and augment wound 
healing cell functions. The focus of this review is the topical application of MSCs directly to 
the wound. There have been animal and human studies showing benefit of MSC therapy in 
the treatment of cutaneous wounds. (Fu & Li 2009) Table 2 details the animal and human 
trials investigating topical MSC therapy in diabetic wounds. Topical MSC therapy is further 
advanced than EPC therapy. The in vivo studies in table 2 demonstrate that topical delivery 
of MSCs result in benefit in diabetic animal cutaneous wounds. It is clear that augmented 
wound repair occurs by differentiation of MSCs to cells with keratinocyte markers and 
paracrine mediated increases in angiogenesis and vessel density. Human studies although 
with a small number of patients have shown benefit with several treatments. Further 
evidence is required from human cells in immunocompromised animal models to assess 
wound healing response. Standardisation in wound healing endpoints in both human and 
animal studies will allow comparison of effect between MSCs and modified MSCs. More 
research is required on the benefit of cells delivered using biomaterials.   
Previous reports have investigated the benefit of topically applied fresh autologous bone 
marrow to wounds and have not been included in the table. In response to wounding and 
ischaemic conditions there is a mobilisation and homing of bone marrow MSCs to the 
wound. MSCs can undergo differentiation and act in a paracrine manner to reduce 
inflammation, stimulate angiogenesis and cause proliferation and migration of other cell 
types involved in wound healing. The MSC secretome is of central importance in realising 
the beneficial paracrine effects of the cells. 
5.2 MSC: Mechanisms of action  
5.2.1 Differentiation 
MSCs may differentiate into mesodermal tissue including osteocytes, chondrocytes and 
adipocytes. They can differentiate into several cell types including cardiomyocytes, vascular 
endothelial cells, neurons, hepatocytes and epithelial cells, making them a potential cell 
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based treatment for human disease.(Volarevic et al. 2011) Allogeneic green fluorescent 
protein labelled bone marrow-derived MSCs have been applied directly to and injected 
around a cutaneous wound. MSC treatment accelerated wound closure, with increased re-
epithelialisation, cellularity and angiogenesis. In the wound the MSCs expressed 
keratinocyte-specific protein keratin and formed glandular structures suggesting MSCs 
contribute to tissue regeneration by differentiating into keratinocytes.(Wu et al., 2007 ) MSCs 
differentiate into epidermal keratinocytes in vivo and in-vitro and also into skin 
appendages{Sasaki et al., 2008;Li et al., 2006).  
5.2.2 Migration/Homing of MSCs 
Bone marrow-derived MSCs contribute to cutaneous wound healing. The homing 
mechanisms are complex. Potential mechanisms include specific receptors or ligands 
undergoing up-regulation in response to injury. This not only facilitates trafficking, 
adhesion and infiltration of MScs but also provide MSCs with a specialised niche to support 
self-renewal and maintain pluripotency.(Si et al., 2011) MSCs  become arrested in blood 
vessels of injured or ischaemic  tissues and secrete a variety of growth factors and cytokines 
beneficial for wound healing.(Karp & Leng Teo 2009) 
5.2.3 Paracrine effects of MSCs 
MSCs act in a paracrine fashion to exert their beneficial effects. MSC-conditioned media 
medium augments wound repair with accelerated epithelialisation. (Wu et al, 2007) The 
analysis of MSC conditioned media revealed cytokines and growth factors required for 
wound healing. Vascular endothelial growth factor-a, Insulin like growth factor-1, 
epidermal growth factor, keratinocyte growth factor, angiopoietin-1, stromal derived factor-
1, macrophage inflammatory protein-1, alpha and beta erythropoietin were increased in 
MSC conditioned media when compared to dermal fibroblast conditioned media. Bone 
marrow-derived MSC conditioned medium attracts macrophages and endothelial 
progenitor cells to wounds.(Chen et al., 2008) MSC paracrine signaling has potential 
beneficial effects on angiogenesis, epithelialisation and fibro-proliferation during wound 
repair (Hocking & Gibran 2010) Wu et al. reported that BM-MSC treated diabetic wounds 
had increased capillary density, but the bone marrow-derived MSCs were not found in the 
new capillary structures. This paracrine effect was supported by analysis of the conditioned 
media which revealed high levels of VEGF-ǂ and angiopoeitin-1 with increased endothelial 
tube formation. (Wu et al., 2007)  
5.2.4 Immunomodulation 
An important characteristic of MSCs is that they express low levels of major 
histocompatibility complex-I (MHC-I) molecules and do not express MHC-II molecules, CD 
80, CD 40 or CD 86 on their cell surface.(Zhang et al., 2010) This allows for allogeneic 
transplantation as MSCs. Human clinical trials have been conducted using allogeneic MSCs 
for the treatment of many conditions including graft-versus-host disease, type-1 diabetes, 
ischaemic heart disease, and neurological disorders e.g. stroke. MSCs possess 
immunosuppressive and anti-inflammatory properties in vitro and in vivo. They may 
suppress the proliferation and function of the innate and adaptive immune response and the  
immunomodulatory functions may occur by direct cell-cell contact or by paracrine 
means.(Zhang et al., 2010) Macrophages are a fundamental cell type in wound healing and 
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immunity. They can be classified as having a pro-inflammatory M1 phenotype or 
polarisation and an anti-inflammatory M2 or wound healing phenotype. MSCs are capable 
of eliciting M2 polarisation of macrophages which contributes to marked acceleration of 
wound healing (Zhang et al., 2010) 
5.3 Optimising MSC therapeutic effect 
The high proliferation capacity of MSCs mean that there is less dose limiting obstacles with 
MSC therapy.  The allogeneic treatment allows for an “off-the-shelf” product. This is possible 
as the cells maybe cryopreserved for use in the future. MSCs are amenable to ex-vivo 
manipulation by gene therapy to provide cellular protection in an ischaemic environment. 
(McGinley et al., 2011). Highly concentrated cell doses can be directly applied to the wound 
surface or adjacent to the wound and delivery can be mediated using biomaterials. (Sorrell & 
Caplan 2010) As is the case with EPCs, biomaterials ensure sustained viability of cells and cell 
encapsulation technology may protect cells from mechanical stress common in diabetic foot 
ulceration. (Anderson et al., 2011;Orive, et al. 2003) Table 2 summarises the published research, 
and includes studies showing the benefit of MSCs on wound healing. There is also a need to 
better understand the stem cell niche involved in diabetic cutaneous wounds.  This is required 
as this niche is the necessary microenvironment for controlling stem cell fate. Tissue 
engineering should provide both cells and adequately functionalised biomaterials in order to 
restore the elements of the stem cell niche. (Becerra et al., 2010)  
  
 
Wound MSC type Delivery Results Mechanism Ref. 
Diabetic 
Mouse 
ulcers 
Human 
chronic 
ulcers 
DFU, n=1 
Autologous
Bone 
Marrow-
Derived 
MSCs 
(BM-MSCs) 
Topical Fibrin 
spray 
↑ Wound 
Closure in mice 
and humans. No 
adverse events 
↑ elastin fibres 
in MSC treated 
wound 
(Falanga et 
al 2007) 
Human 
chronic 
ulcers 
DFU, n=2 
Autologous 
BM-MSCs 
Collagen sponge 
with silicone film
Healing of 
wounds in 18 of 
20 patients 
↑ fibrous, fat 
and vascular 
tissue 
(Yoshikaw
a et 
al.,2008) 
Human 
DFU, n=1 
Autologous 
BM-MSC 
Fresh Bone 
marrow isolate 
applied to wound 
then covered 
with collagen 
seeded with 
MSCs 
↓wound size 
with closing and 
healing of ulcer.
 
N/A (Vojtassak 
et al., 2006) 
Human 
chronic 
wounds 
DFU, n=6 
 
Autologous 
BM-MSCs + 
standard 
wound 
dressing 
MSCs injected in 
and around ulcer, 
and ulcer covered 
by dressing 
↓ ulcer size at 12 
weeks 
Increased 
inflammatory 
cells and 
capillary 
proliferation 
(Dash et 
al., 2009) 
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Wound MSC type Delivery Results Mechanism Ref. 
Diabetic 
rats Full 
thickness 
wounds 
BM-MSCs 
transfected 
with 
hepatocyte 
growth factor
Direct injection to 
wound dermis 
Decreased 
wound healing 
time with 
adHGF MSCs 
↑blood vessels  
↓ collagen 
formation, 
↓ AGEs with 
AdHGF MSCs 
(Ha et al., 
2010) 
Diabetic 
mouse 
with full 
thickness 
ulcer 
Allogeneic 
BM-MSCs 
Topical 
application and 
injection around 
wound edge 
↑wound closure
↑epithelia 
↑cellularity 
↑angiogenesis 
Differentiate 
MSCs to 
keratinocytes 
Paracrine 
↑angiogenesis 
(Wu et al., 
2007) 
Diabetic 
mouse Full 
thickness 
ulcer 
ATSC over-
expressing 
SDF-1 
Topical cell 
application to 
wound 
↑ % wound 
closure 
↓epithelial gap,
↑ cellularity 
Differentiation 
and paracrine 
effect on 
wound cells 
(Di Rocco, 
et al. 2010) 
Diabetic 
Mouse Full 
thickness 
ulcer 
Diabetic 
MSCs co-
applied 
with14S,21R -
diHDHA 
Topical MSCs 
applied to wound 
bed and injected 
intra-dermally 
↑ epithelium 
↑ GT 
 
↑angiogenesis 
due to 
paracrine effect 
(Tian et al., 
2011) 
Diabetic  
mouse Full 
thickness 
Ulcer 
Umbilical 
cord-MSCs 
Topical MSCs or 
systemic  MSCs 
injection 
↓ wound size 
with topically 
applied MSCs 
TGF-ǃ 
Paracrine effect 
(Tark et al., 
2010) 
Diabetic  
mouse 
Full 
thickness 
ulcer 
Autologous
ATSC 
Topical delivery 
using collagen 
scaffold 
↑GT 
↑epithelium 
↑ no, capillary 
 
Paracrine (Nambu et 
al., 2009) 
Diabetic 
Mouse 
ulcer 
Allogeneic
BM-MSCs 
Topical Delivery ↑epithelium 
↑ GT 
↑ blood vessels 
Paracrine (Javazon et 
al., 2007) 
DFU =  Diabetic Foot Ulcer, BM = Bone Marrow, AGE = Advanced Glycation Endproducts 
ATSC = Adispose Tissue-derived stromal cells, GT = Granulation Tissue 
Table II. Animal and human trial on Topical MSC treatment of diabetic wounds 
6. Biomaterial scaffolds for cell therapy in diabetic wound healing 
6.1 Benefit of cell delivery using scaffolds for cell therapy 
As explained above, a limitation of systemic delivery of stem cells is the poor engraftment 
efficiency to the target site, specifically to the wound. It is known that cell infusions e.g. into 
ischaemic muscle, typically result in > 90% of cells rapidly dying. (Silva et al., 2008)  
Therefore some of the failures experienced in clinical cell transplantation may directly arise 
from the manner of administration of the cells rather than a lack of intrinsic bioactivity of 
the cells. (Silva et al., 2008) The use of a matrix is vital to the integrity of cell maintenance 
and growth because cells are anchorage dependent and require an appropriate milieu of 
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mechanical strength, material support, controlled porosity and interconnected channelling 
(Yang et al., 2002)  
6.2 Determining the optimal biomaterial for topical treatment of diabetic wounds 
The goal of developing novel wound healing treatments is to reduce the time to complete 
wound closure and restore the barrier function of the skin. The ideal qualities of a skin 
substitute for diabetic ulcer wound repair is that it will be clinically effective, safe to the 
patient, inexpensive, easy to use, readily available, durable and  encourage cell-matrix 
interactions. The ideal biomaterial should support reconstruction of new tissues without 
inflammation. (Huang & Fu  2010) 
There is a multitude of biomaterials for wound treatments commercially available and 
undergoing research. They may have different physicochemical profiles with differing 
mechanical and degradation properties. They may be synthetic or natural. Natural 
biomaterials are generally considered more biocompatible and similar to the host extra-
cellular matrix. The drawback of synthetic biomaterials is their lack of cellular recognition 
signals. (Huang & Fu 2010) Skin substitutes can be classified based on 1. anatomical 
structure (dermal, epidermal, dermo-epidermal), 2. duration of cover (permanent, semi-
permenant, temporary), 3. type of biomaterial (biological: autologous, allogeneic, 
xenogeneic or synthetic: biodegradable, non-biodegradable), 4. skin substitute composition 
(cellular, acellluar) and 5. Where primary biomaterial loading with cellular components 
occurs(in vitro, in-vivo).(Shevchenko et al., 2010) There are techniques used for 
development of tissue engineered ulcer healing products. These include  1. Transplantation 
of cells without matrix or scaffold, 2. Transplantation of biomaterials alone or with the 
addition of proteins e.g. cytokines and 3. Transplantation of cells in a 3-D scaffold. (Jimenez 
and Jimenez 2004) 
6.3 Currently available cell-based biomaterial dressings for wound healing 
The focus of this chapter is on cell-based treatments using a 3-D scaffold.  There are several 
terms that encompass such skin substitutes i.e. tissue-engineered skin, tissue engineered 
skin constructs, skin substitute bioconstructs, bioengineered skin, living skin replacements 
and living skin equivilants. (Shevchenko et al., 2010) The gold standard skin replacement 
treatment for many conditions has been full-thickness skin grafting. There are inherent risks 
associated with autologous grafts e.g. donor site pain, scarring and infection or delayed 
healing and failure of graft at recipient site. The risks with non-autologous skin grafts 
include immune rejection and infection transmission.  (Wu et al., 2010) A disadvantage of 
the currently available cell-based topical therapies is that they do not address the lack of 
angiogenic properties of the skin substitute. This is important as the successful ability of a 
skin graft to take to an ulcer is an adequate vascular supply. Table III summarises some of 
the commercially available skin substitutes and the clinical indications for their use. Apligraf 
and Dermagraf are temporary treatments for non-healing diabetic ulcers.  These skin 
substitutes are biomaterials seeded with keratinocytes and/or fibroblasts. They are 
indicated as a topical treatment for non-healing diabetic ulcers in the USA.  
6.4 Collagen as a biomaterial 
Collagen is the major extra-cellular matrix protein of the dermal layer of the skin. It forms an 
intrinsic part of blood vessels and supports angiogenesis. It is a commonly used biomaterial 
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for topical cell based wound dressings e.g Apligraf (Organogenesis). It displays low 
antigenicity with purification techniques available to eliminate the immunogenic telo-
peptides.(Huang & Fu 2010) Collagen is appropriate for temporary dressings as it is 
mechanically weak and undergoes degradation on implantation.(Huang & Fu 2010) It is 
possible to manipulate collagen by cross-linking and enhance its physico-chemical 
properties. There are widely used commercial collagen based dressings for diabetic foot 
ulcers (e.g Promogram, which contains oxidised regenerated cellulose by Johnson & 
Johnson). (Zhong et al., 2010) Integra (LifeSciences)  is a wound healing product consisting 
of bovine type 1 collagen cross-linked with chondroitin-6-sulphate which is bonded to a 
silicone membrane. It acts as a template for fibroblast migration and capillary growth in 
vivo. (Zhong et al., 2010) We have successfully seeded stem and progenitor cells in a 
collagen scaffold. Figure 2 is a scanning electron microscope image of EPCs and MSCs 
seeded in a collagen scaffold for 24 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. II. Scanning electron microscope of co-culture of mesenchymal stem cells and early 
endothelial progenitor cells in a type 1 bovine collagen scaffold.  
Erythrocyte 
MSC
EPC
Collagen 
Scaffold 
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Product Description Indication 
Apligraft /Graftskin 
Organogenesis 
Canton, MA, USA 
Allogeneic neonatal foreskin 
keratinocytes and fibroblasts 
seeded in a type 1 bovine 
collagen 
Diabetic foot ulcers 
venous leg ulcers Partial 
thickness burns 
Epidermolysis Bullosa  
Dermagraft 
Advanced Biohealing Inc 
Lojalla,  Ca, USA. 
Allogeneic neonatal 
fibroblasts seeded in a  
polyglycolic acid (Dexon) or 
polyglactin-9-10Vicryl 
scaffold. 
Full thickness DFU 
Epidermolysis Bullosa 
TissueTech Autograft 
system.  
Laserskin and Hyalograft 
Fidia Farmaceutical 
Abano Terme Italy 
Autologous fibroblasts and 
keratinocytes cultured on a 
hyaluronic acid laser 
perforated membrane 
DFU and Chronic 
wounds 
Epicel  
Genzyme Biosurgery 
Cambridge, MA, USA 
Autologous keratinocytes and 
xenogenic proliferation- 
arrested mouse fibroblasts in  
petroleum gauze dressing 
Full thickness burns 
burns taking >30% of 
body area  
Transcyte 
Advanced Biohealing Inc, 
Lojolla California 
Human allogeneic fibroblasts 
cultured on a nylon mesh 
pre-coated with collagen 
Burns 
Transparent dressing 
Orcel 
Ortec International 
New York ,NY USA 
Type 1 Bovine collagen 
seeded with allogeneic 
neonatal fibroblasts and 
keratinocytes 
donor sites for 
autografting, DFU  
Epidermolysis Bullosa 
Epidex 
Modex Therapeutics 
Luzanne 
Switzerland 
Cultured epidermal skin 
equivalent derived from 
keratinocyte precursors of 
human hair follicles  
Chronic Leg uclers 
Myskin 
Altrika  
Sheffield UK 
Autologous keratinocytes 
grown on a silicone layer 
with irradiated murine 
fibroblasts 
Non-healing wounds 
DFU, Burns, Pressure 
ulcers 
Bioseed-S 
BioTissue Technologies 
Freiburg, Germany 
Autologous keratinocytes 
resuspended in a fibrin 
sealant 
Venous leg ulcers 
Permaderm 
Regenicin 
www.regenicin.com 
Autologous keratinocytes and 
fibroblasts seeded on collagen 
biomaterial 
Burns 
Chronic Wounds 
DFU = Diabetic foot ulcers   
 
 
Table III. Sample of currently available Cell-Scaffold skin replacement therapies and their 
indications  
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7. Translation to human therapy 
7.1 Safety and regulatory approval 
With any new cell-based therapy, it is mandatory to ensure safety for the patient. Any 
negative toxic side-effect of cell-based therapies would be a set back for the field of tissue 
engineering and regenerative medicine. In Europe, the European Medicines Agency (EMA) 
controls regulation and clinical trials of new cell based products. In North America, this 
process is under the remit of the Food and Drugs Administration (FDA). The EMA also 
advises on the development of stem cell products which are an example of an advanced 
therapy medicinal product (ATMP). In February 2011, the EMA published a document 
entitled “Reflection paper on stem cell-based medicinal products”, highlighting the current 
situation in the field of stem cell therapy. (EMA 2011)   Safety and clinical efficacy is first 
proven by scientifically robust methodology in pre-clinical studies. It is required that the 
product is produced and clinical trials carried out according to international standards. 
These standards include GLP (good lab practice), GMP (good manufacturing practice), and 
GCP (Good clinical Practice). There is a requirement for quality checks in the manufacturing 
process. This includes analysis of cell treatment batches to ensure cell quality, identity, 
viability and traceability of cells. The goal is a robust, stringently controlled production and 
manufacturing process.  
7.2 Preclinical animal models: choice of model and regulatory issues 
It is necessary to prove treatment efficacy in an animal model. An in vitro wound healing 
model is not sufficient to confirm treatment efficacy. The complexity of diabetic foot 
ulceration with its multi-factorial pathology cannot be realised in an animal model. There 
are over 10 different animal models of diabetic ulceration in the reported literature. There 
are inherent differences between animals and humans. These include cutaneous anatomy, 
vascular supply, duration of diabetes and the presence of other cardiovascular risk factors 
e.g. smoking. 
In addition there are a myriad of endpoints reported in animal wound healing studies. The 
most robust clinically relevant wound healing endpoints are percentage wound closure and 
time to complete healing. The myriad of new treatment modalities under investigation have 
effects on different phases of the wound healing spectrum. The pig has skin felt to be the 
most close to humans but these are large expensive animals. The genetically modified, leptin 
receptor deficient  diabetic mouse is widely used as a model of type 2 diabetes, but wound 
healing occurs by contraction in this model and does not reflect the human situation. The 
rabbit ear dermal ulcer model is a powerful model for examining re-epithelialisation and 
granulation tissue formation in an excisional wound. (Breen et al., 2008) A comprehensive 
review by Lammers et al. recommends a more systematic evaluation of tissue-engineered 
constructs in animal models to enhance the comparison of different constructs, accelerating 
the trajectory to application in human patients. (Lammers et al., 2010) 
The EMA provides advice on the animal models to use for translation of cell-based 
therapy to humans. The choice of the most relevant animal model should be determined 
by the specific safety aspect to be evaluated. It advises the use of human cells to be tested 
in proof of concept and safety studies. This methodology requires the use of immuno-
compromised models either genetically immuno-suppressed or treated with immuno-
suppressants.(EMA 2011) The persistence of cells and the functionality of the cells should 
be assessed. The potential of undifferentiated pluripotent stem cells to form tumours and 
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be genetically unstable due to ex-vivo manipulation requires this to be assessed in animal 
models. This is more likely with embryonic stem cells and pluripotent stem cells. Bio-
distribution of cells to other organs and ectopic tissue formation need to be investigated. 
Prior to first-in-man studies, there are guidelines published by the EMA to identify 
and mitigate risks. Dose finding studies, immunological, pharmacokinetic, pharmco-
dynamic and long term pharmaco-vigilant studies should be undertaken and planned. 
(EMA 2011) 
The use of biomaterials in conjunction with stem and progenitor cells is defined by the EMA 
as a ‘tissue-engineered product’ and falls under the term ATMP.(EU 2007) The experience 
with the development of allogeneic bi-layered skin has provided valuable information on 
the development of skin replacement therapy. Apligraf (Organogenesis), a living bi-layered 
skin substitute has received approval from FDA. It is described as a Class III medical device 
via premarket approval and meets requirements for a human cell, tissue, cellular and tissue-
based product. As the product is made from viable human skin cells, it cannot be terminally 
sterilized, but safety concerns have been addressed. These include risk of transmission of 
infection, immunogenicity, immunological graft rejection and tumour formation. As cells 
are derived from neonatal foreskin, maternal blood of the neonatal donor and the cell banks 
are thoroughly screened for infectious agents, pathogens and other contaminants.(EU 
2007;Wu et al., 2010)  
7.3 Structured diabetic foot care 
Stem and progenitor cell-based topical treatments will not be used in isolation to treat 
diabetic foot ulceration. Ideally, these advanced biological treatments will be part of a 
treatment algorithm, which would see the implementation of standard care prior to use of 
cell therapy. If the restoration of vascular supply, removal of pressure, control of infection 
and debridement of the wound does not succeed in ulcer healing, then the indication for 
cell based therapy would apply. There are analyses of factors associated with lack of 
healing with fibroblast dermal substitutes. An episode of infection during 12 weeks of 
treatment was associated with a 3.4 times increased risk of non-closure of a wound. (Wu 
et al., 2010) High bacterial load in the wound negatively affects wound healing with 
Dermagraft and Browne et al. recommend reducing the bacterial load with combination 
antibiotics prior to the application of skin substitutes. (Browne et al., 2001)  New 
treatment modalities are under investigation which may augment wound healing and 
reduce bacterial load. Plasma therapy may reduce bacterial burden and enhance wound 
healing. (Heinlin et al., 2010) 
7.4 Cost: Benefit analysis 
To ensure development of a successful topical cell based therapy, the product must have 
potential widespread use in the clinical arena. It must demonstrate clinical efficacy in 
clinical trials. In randomised controlled clinical trials the new product must show 
superiority both in comparison to standard care and to other market leaders in the field. It is 
expensive to conduct human clinical trials, therefore the product must demonstrate 
favourable health economics so as to be attractive to health care providers and industrial 
partners. To gain market access, manufacturers have to establish not only the efficacy of the 
product but also whether the product provides a cure at an acceptable cost per unit of health 
gain. (Langer et al., 2009) Several studies have investigated the cost-effectiveness of these 
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products. The results feature favourable cost-effectiveness ratios in selected patient groups 
with chronic wounds. The cost of the product and product development should be offset 
against the total cost of care of the patient with a non-healing diabetic foot ulcer. (Langer et 
al., 2009) There is a need for high quality clinical trials in this area. 
8. Cell-based therapies in other dermatological conditions  
MSCs and EPCs have the potential to treat other dermatological conditions apart from 
diabetic foot ulceration. As seen in table III there are several conditions which may be 
suitable for these therapies including chronic venous and pressure ulcers, burns and 
epidermolysis bullosa. The economic burden of chronic wounds is potentially the largest 
burden on healthcare systems. Stem and progenitor cells may be used as orphan 
medications for life-threatening or extremely rare debilitating conditions. These drugs are 
not developed by large pharmaceuticals and are not subject to the same regulatory process. 
An example of this is the blistering disorder epidermolysis bullosa. In addition research into 
basic stem cell biology will elucidate mechanisms of action of stem cells which may guide 
the development of future therapies. The development of successful skin regeneration and 
elucidation of key molecules and biological systems will allow for scar free repair and 
increased strength of healed wounds. There are further exciting developments in the field of 
stem and progenitor cell therapy for tissue regeneration.  Hair follicle biology is important 
for skin biology and epidermal haemostasis. There are resident stem cells in the bulge area 
of the hair follicle which are required for re-epithelialisation during wound healing. (Wu et 
al., 2011) They are a readily isolatable  source of adult stem cell suitable for autologous 
therapy.(Amoh et al., 2010)  
9. Conclusions 
This book chapter has reviewed the current state of Stem and Progenitor cell therapy for 
non-healing diabetic foot ulceration. The urgent clinical need for developing improved 
novel cell treatments is stressed. The scientific basis for potential success with topical stem 
and progenitor therapy is reviewed. The advantage of using biomaterials to mediate cell 
delivery is discussed. Further developments in tissue engineering will provide more 
intelligent biomaterials which ensure better viability and control of stem cell fate and 
function. The logistical hurdles to translation of bench-side discoveries are reviewed and 
information provided on accelerated development of these advanced medicinal products.   
The importance of translational science is being recognised as a key driver to the realisation 
of basic science discoveries for humans. There are strategic efforts to translate basic science 
to clinical benefit. This bench-to-bedside approach is the focus of government policies 
throughout the world with collaborations developing between pharmaceutical and 
biotechnology industries, academia and clinicians. The success of treatments will rely on 
clinical efficacy, safety, ease of use and cost-effectiveness. The potential to translate this 
technology to a variety of clinical dermatological disorders increases the attractiveness for 
industrial investment for further research and development of these products. A central 
component to the successful translation of this treatment will be the performance of robust 
randomised controlled trials.  Stem cell therapy is a new field encompassing both tissue 
engineering and regenerative medicine science and holds promise for the improved 
treatment of diseases which are suboptimally managed with current therapies. 
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